TERN(Delisted)
Stock Fundamental
Valuation3.9/10
NeutralKey Valuation Metric
PE Method: TERN's market cap is approximately 6.12B with TTM earnings of -9.62B, corresponding to a PE ratio of -63.6. Compared to the Pharmaceuticals industry average, this valuation may be undervalued.
PEG Method: With a PE of -63.6 and forward PE of -63.6, the PEG ratio comes to 1.00, indicating a reasonable valuation.
Historical Price to Earnings Ratio
Historical data shows that TERN's P/E reached a peak of about -1.93 on 2025-04-07, and a trough of about -63.58 on 2026-05-06. The current P/E is -63.58, which places it at approximately the 0% percentile of its historical range, indicating a relatively undervalued valuation.
Share Price vs Future Cash Flow Value
TERN's current stock price is about $52.95, while its Discounted Cash Flow valuation is about $60.35. Based on the Discounted Cash Flow model, the market price represents a price close to its intrinsic value.
Future Growth6.2/10
NeutralEarnings and Revenue Growth Forecasts
Future Return on Equity
Analysts predict TERN's future return on equity (Future ROE) will be about -13.0% over the next three years, lower than the Pharmaceuticals industry average of 82.1%, indicating its backward position in capital profitability. A higher Future ROE generally reflects stronger expected profitability on shareholder equity, subject to business risk and accounting differences.
Past Performance7.3/10
BullishRevenue & Expenses Breakdown
Earnings & Revenue
No earnings data
Free Cash Flow vs Earnings Analysis
TERN's net income is about -12.32M, while free cash flow is about -18.40M, representing a FCF/Earnings ratio of 149.4%. The conversion from earnings to free cash flow is efficient, indicating strong cash generation relative to book earnings.
Financial Health5.5/10
NeutralDebt to Equity History and Analysis
In 2025-12, total liabilities (Debt) are about 18.55M; total equity (Equity) is about 1.01B. These figures come from the financial health diagnose series (debt / equity). They describe capital structure, not operating earnings.
Balance Sheet
Assets
Liabilities + Equity
The company's shareholders' equity is $1.01B, representing about 98.2% of total assets, while total debt is $2.14M, representing about 0.2% of total assets. This low-leverage structure means expansion relies primarily on profits and equity capital, resulting in lower financial risk.
Dividends4.0/10
NeutralStability and Growth of Payments
TERN is not paying a notable dividend in the U.S. market context; detailed stability and growth checks are less relevant until distributions become material.
Dividend Yield vs Market
TERN's current dividend yield is 0.00%, while the Pharmaceuticals industry average is around 3.56%. The top 25% of companies in the entire US market have a dividend yield of 4.56%, while the bottom 25% have a yield of 2.48%. In comparison, TERN is clearly at the bottom of the industry.
Earnings Payout to Shareholders
Earnings coverage: TERN is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash flow coverage: TERN is not paying a notable dividend for the US market.
- Based on a composite score of 6.84/10, we rate TERN as a Netural. Our analysis breaks down into 1.87/10 for Fundamentals, 8.06/10 for Technicals, and 7.06/10 for Sentiment, indicating the stock is likely to consolidate sideways.
- Based on a composite score of 6.84/10, we rate TERN as a Netural. Our analysis breaks down into 1.87/10 for Fundamentals, 8.06/10 for Technicals, and 7.06/10 for Sentiment, indicating the stock is likely to consolidate sideways.
